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Objectives: Hypothyroidism in pregnancy can lead to adverse obstetri-
cal outcomes. Universal screening in pregnant women for thyroid disease 
allows diagnose and treat cases of overt and subclinical hypothyroidism that 
are potentially missed when screening only women at high risk. The objec-
tive of the study was to assess the cost-effectiveness of universal screening 
as an alternative to high risk screening and no screening for thyroid disease 
in pregnant women in Spain. MethOds: The model compared the incre-
mental cost per quality adjusted life-year (QALY) of universal screening ver-
sus high risk screening and versus no screening. A decision analytic model 
was used for the pregnancy and post-partum period. Probabilities from ran-
domized controlled trials were considered for adverse obstetrical outcomes. 
A Markov model was used to assess the lifetime period after the first post-
partum year and accounted for the development of overt hypothyroidism. Main 
assumptions of the model and the use of resources were validated by local 
clinical experts. The analysis considered only direct health care costs (euros 
2013). A 3% discount was applied to costs and QALYs for the period beyond one 
year. Results: Universal screening gained 0.011 QALYs over high risk screening 
and 0.014 QALYS over no screening. Total direct costs per patient were € 5,791 
for universal screening, € 5,796 for high risk screening and € 5,786 for no screen-
ing. Universal screening was dominant compared to risk-based screening and 
highly cost-effective alternative compared to no screening with an ICER of € 374 
per QALY. cOnclusiOns: Universal screening of pregnant women in the first 
trimester for thyroid disease is dominant in Spain compared to the current 
type of screening which is risk-based, as well as cost-effective compared to 
no screening.
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Objectives: To evaluate the cost-effectiveness of intensive glycemic control 
(metformin) combined with fenofibrate in its impact on retinopathy progres-
sion compared to the treatment with metformin only in patients with type 2 
diabetes. MethOds: Design: Markov decision model of retinopathy progression. 
Population: 40-year old patient with type 2 diabetes followed for 29 years. Main 
outcome measures: Risk of visual impairment; incremental cost-effeciveness 
ratio (ICER) for the two treatment options: one combining metformin and fenofi-
brate, and one using solely metformin. Results: Combined tretament of met-
formin and fenofibrate resulted in ICER of -133.06 GBP per QALY which means 
that the intervention is not only effective but is also potentially saving money to 
the National Health Service; tretament solely with metformin is therefore domi-
nated. cOnclusiOns: Results of our study suggest that patients suffering from 
type 2 diabetes will receive from additional treatment with fenofibrate substantial 
benefits of protection against early microvascular complications related to retin-
opathy, including blindness. The favorable cost-effectiveness of intensive glycemic 
control combined with fenofibrate will likely be further increased if other major 
microvascular complications (e.g., non-traumatic amputations) and macrovascular 
complications (e.g., total cardiovascular events) of type 2 diabetes are taken into 
account. Our study is one of the first to compare cost-effectiveness of combined 
treatment of metformin and fenofibrate with current intensive glycemic control 
using solely metformin in its impact on retinopathy progression. Our study also 
provides evidence which may be useful in shaping the current clinical practice in 
the UK and European Union.
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Objectives: Type 2 diabetes (T2D) is characterized by progressive β -cell failure 
in the presence of insulin resistance. The LEAD-6 (Liraglutide Effect and Action 
in Diabetes) clinical trial program compared the efficacy and safety of liraglutide 
once-daily (LIRA) to exenatide twice-daily (EXEN). Few studies have explored the 
real-world effectiveness, and associated costs, of these comparators. Glycemic goal 
attainment of A1C< 7% and total diabetes-related pharmacy costs in clinical practice 
were assessed over 6 months follow-up. MethOds: A retrospective cohort study 
using integrated medical and pharmacy claims and linked A1C results from the 
IMS Patient-Centric Integrated Data Warehouse was conducted. T2D patients ≥ 18 
years naïve to GLP-1, DPP-IV and insulin use during a 6 months pre-index period, 
with evidence of ≥ 1 prescription for LIRA (N= 234) or EXEN (N= 182) between January 
2010 and December 2010 were identified. Only patients who were persistent on 
their index treatment during a 6 months post-index period were included in the 
analysis. The percentage of patients achieving A1C< 7% and total diabetes-related 
pharmacy costs were estimated using multivariable modelling to control for con-
founding effects. The cost per successfully treated patient was calculated as total 
diabetes-related pharmacy costs divided by the percentage of patients achiev-
ing A1C< 7%. Results: The percentage of patients reaching A1C< 7% was 64.4% 
and 53.6% for LIRA and EXEN, respectively (p< 0.05) (baseline A1C mean: 7.8% for 
both LIRA and EXEN). Average total diabetes-related pharmacy costs per patient 
at 6 months were higher for LIRA than EXEN ($2,002 vs $1,799, p< 0.001) but when 
assessed as cost per patient successfully reaching A1C< 7%, LIRA was cost-effective 
compared to EXEN ($3,108 vs $3,354, p< 0.0001). cOnclusiOns: The average cost 
of treating a patient to A1C< 7% at 6 months follow-up was lower with LIRA than 
EXEN. This suggests LIRA to be a cost-effective treatment option compared to EXEN 
in the management of T2D.
the model as to its ability to modify input parameters. The model was externally 
validated against epidemiological data from Russia. Mortality and complications 
risk equations coefficients were modified in accordance with mortality rates due 
to complications in Russia. Cost-effectiveness analysis was performed. Results: 
The developed model allows assessing the risk of more than 15 type 2 DM compli-
cations in 5 years in patients with predefined risk factors. Among comparison of 5 
strategies of type 2 DM therapies (no therapy, vildagliptin, sitagliptin, liraglutide, 
and exenatide) liraglutide was considered the cost-effective strategy with ICER/
QALY - 470120.40 RUR, which is 51% of the willingness-to-pay threshold in Russia. 
With the lowest complication treatment costs inside the total direct costs, liraglu-
tide monotherapy demonstrated the most long-term sustainable blood glucose 
control and HbA1c goal parameters. cOnclusiOns: The developed model allows 
increase in compliance of therapy. Possibility of individual choice of the most 
cost-effective treatment regimen for each patient leads to so-called “personal-
ized” therapies.
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Objectives: To estimate the resource utilization and related costs for Polish acro-
megalic patients treated with lanreotide AUTOGEL 120 mg (ATG120) in routine 
clinical practice MethOds: Medical care resource (dosage regimens, diagnostic 
procedures, hospitalizations, out-patient visits, any treatment changes) were col-
lected during 1-year retrospective phase of non-intreventional, observational study 
(Lanro-Study). The study population consisted of acromegalic patients treated for 
at least three injections with ATG120. The endpoints were: proportion of patients 
treated for acromegaly with a given pharmaceutical in a given dosing interval, 
resource utilization, costs per patient/month or year. Costs were calculated in 
PLN from the public health-care payer perspective for the year 2013 (1 EURO = 4.2 
PLN). Results: A otal of 143 patients were included in the analysis (72% women, 
80% macroadenoma, 72% previous pituitary surgery). Changes in the treatment 
scheme were reported in 54 patients. The mean cost of treatment in patients who 
switched from octreotide LAR (LAR) to ATG120 (n= 26) was 6060.01 PLN/patient/
month with LAR and 4047.96/patient/month PLN when switched to ATG120. At the 
time all patients entered the prospective phase, and were receiving ATG120, the 
mean cost of treatment with ATG120 was estimated at 3941.84 PLN/patient/month. 
Most patients (n= 100; 70%) received ATG120 at dosing intervals less frequent than 
every 4 weeks. Patients were predominantly treated in out-patient setting with 4.77 
physician visits/patient/year, most common control examinations were magnetic 
resonance imaging of brain and brain stem (0.57/patient/year), ultrasound of neck 
(0.55/patient/year), and IGF-1 (1.96/patient/year), GH (1.49/patient/year), glycemia 
(0.91/patient/year), pituitary-thyroid axis hormones (TSH- 0.45/patient/year, T4-0.49/
patient/year). Only 7.7% patients were hospitalized. The mean medical cost, exclud-
ing pharmacotherapy, was 1002 PLN/patient/year. cOnclusiOns: These results 
represent the current use of ATG120 in the population of Polish acromegalic patients 
in a realistic clinical settings and indicate that this therapy may provide cost saving 
in comparison to octreotide LAR.
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Objectives: To assess the treatment pattern, dosage and costs of lanreotide 
AUTOGEL 120 (L-ATG120) administered as part of routine acromegaly care in 
Poland. MethOds: Lanro-Study is a multicenter, non-interventional, observa-
tional study on resource utilization in the population of Polish acromegalic patients 
treated with L-ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study 
recruited adult acromegalic patients treated medically for ≥ 1 year, including at least 
3 injections of L-ATG120. Data on dosing interval and aspects of administration were 
collected prospectively during 12-months (interim analysis). Costs were calculated 
in PLN from the public health care payer perspective for the year 2013 (1 EURO = 
4.2 PLN). Results: A total of 139 patients were included in the analysis. Changes 
in dosing regimen were reported in 14 (9.4% ) patients, polytherapy was used in 11 
(8%) patients. 70 patients (50%) received L-ATG120 at an extended dosing interval (> 
4 weeks), the mean number of days between injections was 35.56 (SD 8.4). L-ATG120 
was predominantly administered in out-patient setting (77%), by health care profes-
sionalists (94%). Mean time needed for preparation and administration was 4.33 and 
1.58 min., respectively, mean product wastage – 0.13 mg. The cost of L-ATG120 was 
estimated at 4103.87 PLN/patient/month cOnclusiOns: These results represent 
the current use of L-ATG120 in the population of Polish acromegalic patients in a 
realistic clinical settings. Findings that 50% of patients could be treated with dose 
intervals of longer than 28 days support the potential for L-ATG120 of reducing 
treatment burden.
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